Matthew Emmens
Nessuna posizione attualmente
Profilo
Matthew W. Emmens è un uomo d'affari americano che è stato a capo di 6 diverse aziende è nel consiglio di amministrazione di Bristol Myers Squibb Co. Nella sua carriera passata ha occupato la posizione di direttore presso Vertex Pharmaceuticals, Inc, presidente e direttore presso Merck KGaA e presidente e amministratore delegato per EMD Pharmaceuticals, Inc. (una filiale di Merck KGaA), Presidente non esecutivo di Shire Plc, Amministratore delegato di Shire Plc, Presidente e Amministratore delegato di Astra Merck, Inc. e Direttore delle relazioni con gli investitori di New River Pharmaceuticals, Inc. Il signor Emmens si è laureato presso la Fairleigh Dickinson University.
Precedenti posizioni note di Matthew Emmens
Società | Posizione | Fine |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | 04/05/2021 |
SHIRE | Chairman | 29/04/2014 |
INCYTE CORPORATION | Director/Board Member | 04/02/2009 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Chief Executive Officer | 23/05/2008 |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Director/Board Member | 12/03/2008 |
Formazione di Matthew Emmens
Fairleigh Dickinson University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
INCYTE CORPORATION | Health Technology |
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
MERCK KGAA | Health Technology |
Aziende private | 6 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Shire Acquisition, Inc.
Shire Acquisition, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands. | Health Technology |
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Astra Merck, Inc.
Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a private company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Health Technology |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | Health Technology |
- Borsa valori
- Insiders
- Matthew Emmens